Plasminogen Activation System in Rectal Adenocarcinoma.
BACKGROUND
The purpose of the present study was to determine the extent of expression of proteins that are the elements of the plasminogen activation system, i.e. urokinase plasminogen activator (uPA), receptor of uPA (uPAR), plasminogen activating inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) in the primary site of rectal adenocarcinoma, as well as in lymph node metastases, and their correlation with clinical and pathological data.


METHODS
The study material consisted of archival paraffin blocks from 108 patients with confirmed oncological diagnosis, treated in 2002 and 2003 in the Lower Silesian Oncology Centre in Wroclaw. This material was used for immunohistochemical reactions with antibodies against uPA, uPAR, PAI-1 and tPA. The extent of expression was evaluated semi-quantitatively based on the immunoreactive score according to Remmele and Stegner. The obtained results were correlated with clinical and pathological data: stage of the disease (modified Dukes' classification of Astler and Coller), grade of histological malignancy, event-free survival and overall survival.


RESULTS
It was found that cytoplasmic expression of uPA, uPAR, PAI-1 and tPA was higher in cells of tumor and metastases of perienteric lymph nodes in comparison to normal rectal tissues. Positive correlation was shown between expression of PAI-1 and tPA, uPA and uPAR, as well uPA and PAI-1 (r=0.70, r=0.77 and r=0.34, respectively; p<0.05 for all). Additionally, in patients with low and moderate expression of uPA and uPAR, the overall survival rate was higher in comparison to patients with high expression of the studied markers.


CONCLUSIONS
The intensity of expression of uPA and uPAR might be a prognostic factor of survival time for patients with primary rectal adenocarcinomas.
Second Department of Radiotherapy, Lower Silesian Oncology Centre, Wroclaw, Poland.
Elzbieta
E
Razik
Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland Department of Physiotherapy, University School of Physical Education, Wroclaw, Poland ch.kobierzycki@gmail.com.
Christopher
C
Kobierzycki
Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland.
Jedrzej
J
Grzegrzolka
Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland.
Marzenna
M
Podhorska-Okolow
Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland.
Malgorzata
M
Drag-Zalesinska
Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland Department of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland.
Maciej
M
Zabel
Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland Department of Physiotherapy, University School of Physical Education, Wroclaw, Poland.
Piotr
P
Dziegiel
D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D010958:Plasminogen / Q000378:metabolism*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D011379:Prognosis; D055293:Receptors, Urokinase Plasminogen Activator / Q000378:metabolism*; D012004:Rectal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D010959:Tissue Plasminogen Activator / Q000378:metabolism*; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D014408:Biomarkers, Tumor; D017395:Plasminogen Activator Inhibitor 1; D055293:Receptors, Urokinase Plasminogen Activator; C051321:SERPINE1 protein, human; D010958:Plasminogen; C067262:PLAT protein, human; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
PAI-1; Plasminogen activation system; rectal adenocarcinoma; tPA; uPA; uPAR